CEDAR KNOLLS, N.J.--(BUSINESS WIRE)--Emisphere Technologies, Inc. (NASDAQ: EMIS) today announced that it has received a $500,000 milestone payment from MannKind Corporation in connection with MannKind’s recent filing and the U.S. Food & Drug Administration's (FDA’s) acceptance of MannKind’s New Drug Application (“NDA”) for AFRESA®, an ultra rapid-acting insulin.
